A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types - Wikidata - wikimedia - TriplyDB

A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types

A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types

http://www.wikidata.org/entity/Q35215580

about

PI3K isoform-selective inhibitors: next-generation targeted cancer therapies Growth factor signaling to mTORC1 by amino acid-laden macropinosomes.CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function.Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development PI3Kγ integrates cAMP and Akt signalling of the μ-opioid receptor.The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment Class II phosphoinositide 3-kinases contribute to endothelial cells morphogenesis.Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer Oncogenic mutations of p110α isoform of PI 3-kinase upregulate its protein kinase activity.PKD1 mediates negative feedback of PI3K/Akt activation in response to G protein-coupled receptors.Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.Phosphoinositide 3-kinase (PI3K(p110alpha)) directly regulates key components of the Z-disc and cardiac structure.Phosphoinositide 3-kinase alpha-dependent regulation of branching morphogenesis in murine embryonic lung: evidence for a role in determining morphogenic properties of FGF7 Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.Definition of the binding mode of a new class of phosphoinositide 3-kinase α-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis.Perturbations of PIP3 signalling trigger a global remodelling of mRNA landscape and reveal a transcriptional feedback loop.Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition.PI3 kinases p110α and PI3K-C2β negatively regulate cAMP via PDE3/8 to control insulin secretion in mouse and human islets.Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome.Mutational analysis of breast cancer: guiding personalized treatments Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas.Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.The adherens junction protein afadin is an AKT substrate that regulates breast cancer cell migration.A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.Phosphoinositide 3-kinase α inhibitors: a patent review.Structure, function and inhibition of the phosphoinositide 3-kinase p110α enzyme.PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma.

P2860

Q26781294-6756B1A0-EF08-4227-8F2A-AF1DE4814838 Q27309327-C29651C4-2B17-4A10-A8CF-8BD9C2A833C3 Q27853037-03D39BFF-B0B5-4F9A-AB1B-01AD45043F89 Q28247338-FC9BEB5C-922D-4B97-839F-D7779102A42E Q31070331-00F47BBA-2A6F-47D4-AABF-7D815150B4EF Q33734538-7D9A9CD3-F439-4F08-8BB3-1FFE619EB6B5 Q33776641-BF3ECD62-43C9-404B-B2DB-36DE093DAC3B Q33842781-0CBCB913-E515-4B0C-95A6-C8623EC9A8DC Q34096861-76D45162-24E1-4222-8347-FEF34CC823C5 Q34508976-8B6777D3-D0E8-4FE6-8A79-A2D83C16E495 Q34548346-86AEF143-7E13-429C-B089-F02C69B2AF6C Q34590266-35C19F1B-B1CF-4344-A0A4-5DA31F59ABF9 Q34600369-4EFD21D4-294C-4D50-93D2-0AB8E3368897 Q34629544-DFE02897-347F-440B-AE2C-3F4AE3685E86 Q34926681-94CF07DC-7BF9-4AA0-BD8C-93A8E0A47309 Q34988846-9B4880CE-92C2-4352-AFBB-A9B8775AEAE6 Q35143738-382B2D55-B356-49A7-BF76-2A8836FC7127 Q35182995-30A56CBB-8C83-4CDF-A621-A067B508E96E Q35474166-DBDF919F-661E-41D5-9FC1-46D01B232D54 Q35657827-4A050ADC-58F7-4645-8087-14EF91633581 Q35746524-5E7B17DD-178C-4F25-B22F-90F6E5CD3385 Q36327175-81C16A33-3378-46BC-A84E-77F93989EA80 Q36676531-1F09A893-DF99-46B9-9EFB-5E0C1A2B22B1 Q36705677-C7707448-265B-4B3B-94F8-D1940A5B1076 Q36709839-7CF58C8F-685C-440E-B264-24C013464F8C Q36771317-58402B0B-BA14-4F61-AC52-D213FE39AE8A Q36899519-9B772A3A-AD38-4DB3-A128-084D2DA07712 Q37039735-961398C9-FEC7-4A66-8099-1CD0FDDACC4B Q37064604-A374DE88-F334-4F90-93ED-B3F52B999147 Q37208553-E0CEC45F-C97D-4BF3-9F12-68D340221B35 Q37215752-F2A47E8D-9B39-49B0-88E4-750E8A16D176 Q37371256-3C65B53B-280D-42A7-B86A-73C3B4DD8BA3 Q37578817-5EEBCA7F-0CA7-41EF-894F-D57EBCBB78A2 Q37656357-63F69F44-6557-49A2-BB58-865244B8ACFD Q37729587-7DBD1313-6868-452F-8EAF-39A3EE39CCA9 Q37976467-E73E1839-A508-4E6F-8852-D8E4892B06E0 Q38042638-EA919635-7416-412E-8053-B04915E6BA25 Q38089138-47058272-D3C6-4240-8B69-3E4195BA79BB Q38180768-94988467-E584-4311-8BF3-A9ACE79773BF Q38805492-B92CA5CB-4C66-4894-AAA3-8EFE7EBE0BD8

P2860

A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types

http://www.wikidata.org/entity/Q35215580

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A drug targeting only p110α ca ...... r growth in certain cell types

@ast

A drug targeting only p110α ca ...... r growth in certain cell types

@en

type

label

A drug targeting only p110α ca ...... r growth in certain cell types

@ast

A drug targeting only p110α ca ...... r growth in certain cell types

@en

prefLabel

A drug targeting only p110α ca ...... r growth in certain cell types

@ast

A drug targeting only p110α ca ...... r growth in certain cell types

@en

P1433

Q35215580-6B67C168-068B-4D95-8035-4C9D84931DE3

P1476

Q35215580-740EF3F3-98BC-4D38-84E3-BFC783FCC527

P2093

Q35215580-14B1AFC5-7548-4387-ADA0-DCCC6DA6096E

Q35215580-369D26F3-6230-45A6-A930-3D6001634E84

Q35215580-393258E3-B020-4A35-9413-4344B43E869C

Q35215580-4E289ECF-27B5-4892-97A0-F16D61259FB8

Q35215580-6322968F-B56F-4B92-A6E3-40B411FD0A72

Q35215580-666C3BAA-F64B-455B-A816-5563042D250C

Q35215580-9B6D66EE-9EFB-43F3-B759-D2F31ABF6383

Q35215580-CED86794-D8B0-415E-9601-304E64B1A6AF

Q35215580-D48C539D-BE3E-44EA-B505-0D3623F5879F

Q35215580-DC8E0072-1B03-4CE9-981D-6BE70E154369

P2860

Q35215580-03B962AC-465F-4C57-A45E-24B43B459F96

Q35215580-0DA6915B-8790-44DC-B9CF-456E23402486

Q35215580-114F8C2A-9A44-4E5D-A3A6-F355116E63A2

Q35215580-1170966A-A6C3-429B-9C53-A9E7EEB22198

Q35215580-1599F3B0-7DA0-4252-B86F-70FCEACA1BE7

Q35215580-1E49B9A5-40EA-4CE0-AC8E-83F00E980DF2

Q35215580-256DB33E-7BE7-457E-A54D-3E2DBBF74811

Q35215580-2BA4196D-28E4-4090-BF1D-4696B6D3F3A5

Q35215580-398B782B-B949-45D6-96E3-608EEB704A23

Q35215580-3F6847ED-0221-45FC-BF2E-A6304A30CC12

P304

Q35215580-40305875-B074-49CA-B05A-BDF9285E953C

P31

Q35215580-430EEAB0-84BC-46AA-A683-6799976231FB

P356

Q35215580-5262A061-CEF3-4764-ACD4-DA0FA7E6D35A

P407

Q35215580-C808B989-F850-4788-BADC-8C8C4769A6F0

P433

Q35215580-52445EC8-DD3A-4F1E-AA8A-B95FBDF868A3

P478

Q35215580-FB80CF10-026F-46CF-ABCE-0745E57EFAFF

P577

Q35215580-E36CCA34-14EE-47F5-B885-CE50058CF5DF

P698

Q35215580-E0B8BBDB-8400-4D2F-98DF-76A1C619B2A8

P932

Q35215580-C47CEC43-99C4-4304-903F-EE6E73386A7C

P356

P1433

Biochemical Journal

P1476

A drug targeting only p110α ca ...... r growth in certain cell types

@en

P2093

Bruce C Baguley

http://www.w3.org/2001/XMLSchema#string

Christina Buchanan

http://www.w3.org/2001/XMLSchema#string

Gordon W Rewcastle

http://www.w3.org/2001/XMLSchema#string

Jack U Flanagan

http://www.w3.org/2001/XMLSchema#string

Jackie D Kendall

http://www.w3.org/2001/XMLSchema#string

James Dickson

http://www.w3.org/2001/XMLSchema#string

Peter R Shepherd

http://www.w3.org/2001/XMLSchema#string

Ripudaman Singh

http://www.w3.org/2001/XMLSchema#string

Sharada Kolekar

http://www.w3.org/2001/XMLSchema#string

Stephen Jamieson

http://www.w3.org/2001/XMLSchema#string

P2860

PTEN function: how normal cells control it and tumour cells lose it

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

MolProbity: all-atom structure validation for macromolecular crystallography

Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations

A frequent kinase domain mutation that changes the interaction between PI3K and the membrane

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

High frequency of mutations of the PIK3CA gene in human cancers

Targeting phosphoinositide 3-kinase: moving towards therapy

PI 3-kinase p110beta: a new target for antithrombotic therapy

P304

53-62

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1042/BJ20110502

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

438

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21668414

http://www.w3.org/2001/XMLSchema#string

P932

3174055

http://www.w3.org/2001/XMLSchema#string